Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Purpose of Review: This review seeks to detail the clinical and pathologic features specific to BRAFV600E colorectal cancer. Application of novel preclinical findings translated into the clinic for the development of new therapeutic options for patients with BRAFV600E metastatic colorectal cancer will be detailed. Recent Findings: While BRAF inhibitors as monotherapy do not have the same clinical activity for colorectal cancer relative to other solid tumors harboring an oncogenic BRAFV600E mutation, combination approaches targeting BRAF + MEK + EGFR hold promise for patients with BRAFV600E colorectal cancer. Summary: Simultaneous targeting of multiple drivers along the MAPK pathway improves clinical outcomes for patients with BRAFV600E colorectal cancer. Targeted therapies and immunotherapy hold great promise in the years to come for patients with this subtype of colorectal cancer.

Original languageEnglish (US)
Pages (from-to)53-60
Number of pages8
JournalCurrent Colorectal Cancer Reports
Volume15
Issue number2
DOIs
StatePublished - Apr 15 2019

Keywords

  • BRAF
  • Biomarker
  • Clinical trial
  • Colorectal cancer
  • Immunotherapy
  • Targeted therapy

ASJC Scopus subject areas

  • Hepatology
  • Oncology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies'. Together they form a unique fingerprint.

  • Cite this